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3 A 2018 Cochrane review found that omega-3 supplementation in pregnancy was associated 
4 with a risk reduction of early preterm birth of 0.58; prompting calls for universal 
5 supplementation. Recent analysis suggests the benefit may be confined to women with a low 
6 baseline omega-3 fatty acid status, however the contemporary UK pregnant omega-3 fatty 
7 acid status is largely unknown. This is particularly pertinent for women with a previous 
8 preterm birth, in whom a small relative risk reduction would have a larger reduction of 
9 absolute risk. 
10 This study aimed to assess the omega-3 fatty acid status of a UK pregnant population and 
11 determine the association between the long-chain omega-3 fatty acids and recurrent 
12 spontaneous early preterm birth.  
13 Materials and Methods
14 283 high-risk women with previous early preterm birth were recruited to the prospective 
15 obstervational study in Liverpool, UK. Additionally, 96 pregnant women with previous term 
16 births and birth ≥39+0 weeks in the index pregnancy provided a low-risk population sample.
17 Within the high-risk group we assessed the odds ratio of recurrent early preterm birth 
18 compared to birth at ≥37+0 weeks gestation according to plasma eicosapentaenoic acid plus 
19 docosahexaenoic acid (EPA+DHA) at 15-22 weeks gestation. 
20 Results
21 Our participants had low EPA+DHA; 62% (143/229) of women with previous PTB and 69% 
22 (68/96) of the population sample had levels within the lowest two quintiles of a previously 
23 published pregnancy cohort.   
24 We found no association between long-chain omega-3 status and recurrent early preterm 
25 birth (n=51). The crude odds ratio of a recurrent event was 0.91 (95% CI 0.38 to 2.15, 
26 p=0.83) for women in the lowest, compared to the highest three quintiles of EPA+DHA.  
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2 In the majority of our participants levels of long-chain omega-3 were low; within the range 
3 that may benefit from supplementation. However, levels showed no association with risk of 
4 recurrent early sPTB. This could be because our population levels were too low to show 
5 benefit in being omega-3 ‘replete’; or else omega-3 levels may be of lesser importance in 
6 recurrent early preterm birth.
7
8 Keywords
9 Preterm birth, omega-3, long-chain polyunsaturated fatty acids
10
11 Abbreviations
12 BMI: Body mass index
13 DHA: Docosahexaenoic acid
14 EPA: Eicosapentaenoic acid
15 IMD: Index of multiple deprivation
16 LLETZ: Large Loop Excision of Transformation Zone of cervix
17 PPROM: Preterm Prelabour Rupture of Membranes
18 sPTB: Spontaneous preterm birth
19
20 Key message
21 UK pregnant women have low omega-3, whether they have had a previous preterm birth, or 
22 not. Surprisingly levels don’t relate to recurrent early preterm birth risk. Should we 
23 supplement?
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3 Globally preterm birth is the leading cause of death in children under 5 years old.1 Previous 
4 preterm birth is the strongest risk factor for subsequent preterm delivery.2 A 2018 Cochrane 
5 review concluded that omega-3 supplementation was an effective strategy to prevent preterm 
6 birth, with a 42% risk reduction (from 46 to 27 per 1000 births; 95% CI, 23-56) for preterm 
7 birth less than 34 weeks.3 A subsequent randomised controlled trial4 with secondary analysis5 
8 suggested the benefit may be confined to women with a low baseline total long chain omega-
9 3 fatty acid level. Worryingly, within the secondary analysis5 supplementing women with 
10 higher total long chain omega-3 fatty acid status was associated with increased rates of early 
11 preterm birth.
12 The fatty acid components with the strongest evidence of preterm birth prevention are 
13 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA),3 which are collectively 
14 referred to as long-chain omega-3 fatty acids. These nutrients are predominantly obtained 
15 from oily fish and seafood and associated with a more affluent diet. The long-chain omega-3 
16 intake in pregnancy in the UK has been estimated from food frequency questionnaires as 
17 low,6,7 or adequate8 in three studies between 1991 and 2007. 
18 Liverpool Women’s Hospital has a tertiary referral preterm birth prevention clinic that serves 
19 the 4th most deprived local authority area in England (out of 343).9 Based on the Cochrane 
20 review3 findings we offered omega-3 supplementation to these high risk women from 
21 February 2019.10 However, we were unsure whether this would offer benefit because of the 
22 unknown baseline long-chain omega-3 status in our population.  Plasma levels of omega-3 in 
23 the UK pregnant population have not been assessed to our knowledge. The Danish National 
24 Birth Cohort11,12 showed that women in the lowest quintile of plasma EPA+DHA (<1.42% of 
25 total fatty acids), in the second trimester, had a 2.13 times increased risk (95% CI 1.18-3.79) 
26 of sPTB under 34 weeks compared to women in quintiles 3-5. The association between 
27 omega-3 and preterm birth was not present with levels in the third quintile and above. This is 
28 consistent with Simmonds et al5 and suggests that the main benefit of supplementation is in 
29 pregnancies with a lower baseline long-chain omega-3 status.
Page 7 of 32
http://www.aogs-online.com































































1 Importantly there has been a recent corrigendum12 to the original research within the Danish 
2 National Birth cohort11 based on the effect of thawing of stored samples prior to analysis of 
3 long-chain omega-3 fatty acids; this was therefore addressed within our analysis too. 
4 We had two objectives. Firstly, to determine the expected distribution of long-chain omega-3 
5 fatty acids within ‘healthy pregnancies’ in our locality; low-risk pregnant women who 
6 delivered at ≥39 weeks without preterm prelabour rupture of membranes (PPROM). 
7 Secondly, to assess the relationship between long-chain omega-3 status and recurrent early 
8 (under 34+0 weeks) spontaneous preterm birth (sPTB) and PPROM in our region. 
9 MATERIALS AND METHODS
10 Women with singleton pregnancies were enrolled at Liverpool Women’s Hospital from 1st 
11 April 2012 until 31st December 2017 as part of “The development of novel biomarkers for 
12 prediction of preterm labour in a high-risk population study”. Participants were invited to two 
13 visits at approximately 16 (15+1-18+6 weeks) and 20 weeks gestation (19+0-23+0). For the 
14 purposes of this analysis the first sample available was used (single sample per participant). 
15 A flowchart of selection entry from two different obstetric populations is shown in Figure 1. 
16 A ‘high-risk’ population consisted of women with a history of sPTB or PPROM at 16+0-33+6 
17 weeks gestation. Low-risk women were parous women with all previous births ≥37+0 weeks 
18 gestation. Full details of the recruitment process, inclusion criteria and careful pregnancy 
19 outcome classification criteria are given in Appendix A. Participants were excluded from the 
20 statistical analysis if omega-3 supplements had been used in pregnancy.
21 To describe the expected distribution of omega-3 fatty acids in our population low-risk 
22 women that delivered ≥39+0 weeks were selected (low-risk population sample). 
23 Recurrent early sPTB/PPROM was defined as high-risk participants who had a late 
24 miscarriage, PPROM or sPTB at 16+0-33+6 weeks gestation. High-risk women who gave birth 
25 ≥37+0 weeks gestation without PPROM were allocated to the high-risk term birth group.  
26
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1 Omega-3 fatty acid analysis
2 Maternal blood samples were taken in 10ml BD vacutainer® tubes containing K2EDTA 
3 (dipotassium ethylenediaminetetraacetic acid), placed on ice immediately and processed 
4 within 1 hour of sampling. Tubes were centrifuged at 3000rpm for 10mins at 4°C. Plasma 
5 was aspirated and stored in cryovials at -80°C. A total of 30uL was transferred to blood spot 
6 cards that were coated in antioxidants and chelating agents so as to minimise oxidation of 
7 polyunsaturated fatty acids.13 The dried blood spot cards transported by post to SAHMRI 
8 (South Australian Health and Medical Research Institute) where the plasma spots were 
9 transesterified and distributions of fatty acids were determined by capillary gas 
10 chromatography.13 The laboratory team were blinded to the pregnancy status of the samples.
11 Statistical analysis
12 Statistical analysis was performed in Stata version 15.1. The distribution of long-chain 
13 omega-3 fatty acids within the low-risk population sample were calculated and used to define 
14 quintiles of total omega-3, DHA and EPA for our population.
15 Histograms were used to show the distribution of long-chain omega-3 fatty acids within the 
16 high-risk group according to whether the participant did, or didn’t, have recurrent early 
17 sPTB/PPROM.  Two-term fractional polynomials were then used to visualise the expected 
18 non-linear association between long-chain omega-3 fatty acids levels and risk of recurrent 
19 early sPTB/PPROM within the high-risk group.
20 High-risk participants in the early sPTB/PPROM and high-risk term birth groups were 
21 assigned to the quintiles based on the distribution of total omega-3, DHA and EPA within the 
22 low-risk population sample and to the quintiles described by Olsen et al.11,12  Binomial 
23 logistic regression was used to calculate the odds ratios of early sPTB/PPROM compared to 
24 term birth per quintile. Quintiles 3-5 were combined and used as the reference group based 
25 on previous work.11,12 Analysis was performed unadjusted and adjusted for covariates that 
26 were selected based on biological plausibility. The chosen covariates were: maternal age at 
27 study participation; maternal body mass index (BMI); maternal smoking at time of study visit 
28 (binary outcome of yes/no); and index of multiple deprivation (IMD). Age and BMI were 
29 converted to quadratic terms because of the bimodal relationships between these variables 
30 and risk of preterm birth. IMD was obtained using the woman’s home postcode on the UK 
31 government website.14 The IMD ranks every neighbourhood in England from 1 (most 
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1 deprived) to 32844 (least deprived).9 The IMD is a collective score summarising income 
2 deprivation, employment deprivation, health deprivation and disability, education skills and 
3 training deprivation, barriers to housing and services, living environment deprivation, and 
4 crime. IMD scores were used as continuous variables within the logistic regression.
5 Adjusted odds ratios for early sPTB/PPROM are presented both for the participants with all 
6 co-variates available, and for all participants using imputation for missing co-variates. 
7 Multiple imputation using chain equations was used to account for missing data as this allows 
8 for binary covariates (such as smoking). The proportion of total sampling variance due to 
9 missing data for IMD was 48%, therefore as recommended 50 imputations were performed.15 
10 The variables used in the imputation model were all of the covariates described above as well 
11 as: pregnancy outcome (birth at term or early sPTB/PPROM); quintile of total omega-3, 
12 EPA, DHA and DHA plus EPA; and quintile according to Olsen et al.11,12 No auxiliary 
13 variables were identified.
14 During the course of this work concern was raised that prior thawing may alter plasma long-
15 chain omega-3 fatty acid analysis.12 We therefore undertook three further pieces of statistical 
16 analysis. Firstly, assessment was performed of the long-chain omega-3 fatty acid status by 
17 number of prior freeze-thaw cycles of the sample. Secondly the number of freeze thaw cycles 
18 was included as a covariate in the logistic regression described above. Finally the binomial 
19 logistic regression was repeated using only samples that had undergone prior freeze-thaw 
20 cycles, and those without.
21 Ethical approval
22 The study was approved by North West Research Ethics Committee- Liverpool Central, 
23 reference 11/NW/0720 on 4th November 2011.
24
25 RESULTS
26 We recruited 296 high-risk participants and 271 low-risk participants. Of 283 high-risk 
27 women with data suitable for analysis, 51 (18%) had a recurrent early sPTB or PPROM and 
28 178 (63%) had term births (≥37weeks) without PPROM (Figure 1). Of 271 low-risk 
29 participants, 188 gave birth at ≥39+0 weeks without PPROM, and had samples suitable for 
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1 analysis. We selected the first 100 of these participants to send samples for laboratory 
2 analysis. Four of these participants were subsequently noted to have used omega-3 
3 supplementation, and so the remaining 96 participants formed the low-risk population 
4 sample. 
5 The baseline characteristics and pregnancy outcomes are broadly similar across the 
6 pregnancy groups (Table 1), except for known risk factors for sPTB/PPROM. Compared to 
7 the low-risk population sample, more of the high-risk participants smoked (9.7% of low-risk  
8 vs 24.0% of high-risk group), and the high-risk participants had slightly lower IMD scores 
9 (more social deprivation). Preterm birth prevention treatment was offered in accordance with 
10 UK national guidelines.16 None of the low-risk women required an intervention but 32.8% 
11 (93/283) of the high-risk women did. 
12 The low-risk population sample were used to define the expected distribution of omega-3 
13 fatty acid levels in our population (Table 2). 
14 Levels of total omega-3, DHA and EPA within the high-risk group show similar distributions 
15 in women who have an early sPTB/PPROM, and those who do not (Figure 2 A-D). The risk 
16 of recurrent early sPTB by total omega-3, DHA and EPA levels are visualised in Figure 2 E-
17 H. Visually, it appears there could be a weak relationship between higher levels of EPA, 
18 DHA and total omega-3 and preterm birth, but the wide confidence intervals are also 
19 consistent with no correlation. 
20 The high-risk group was then split according to total omega-3, DHA and EPA quintiles 
21 obtained from low-risk population sample into three groups: quintile 1, 2 and 3-5 (reference 
22 group) (Table 3).  When pregnancy outcomes were compared between quintile groups, the 
23 early sPTB/ PPROM rate was lower in quintiles 1 and 2 for total omega-3 (crude OR 0.65, 
24 95% CI 0.23-1.84 and 0.52, 95% CI 0.23-1.15, respectively), EPA plus DHA, DHA and 
25 EPA, although none of these differences reached conventional statistical significance 
26 (p<0.05) (Table 3).  
27 We performed the same analysis adjusting for covariates of smoking, maternal age, BMI, and 
28 IMD, both restricting the analysis to participants with all variables available and using 
29 multiple imputation to account for missing variables (Table 3). These results also showed no 
30 association between long-chain omega-3 fatty acids and early sPTB/PPROM, and the non-
31 significant trend towards higher risk of preterm birth with higher levels.
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1 Omega-3 fatty acid levels were universally lower in our population than the Danish National 
2 Birth Cohort11,12 (Table 4).  66% (63/96) of our low-risk population sample had plasma 
3 DHA+EPA levels within the lowest two quintiles of the Danish cohort (compared to the 
4 expected 40%). Levels within the lowest two quintiles of the Danish cohort were also found 
5 in 51% (26/51) of high-risk women who had recurrent early sPTB/PPROM and 56% 
6 (100/178) of high-risk women who had term births. Unadjusted and adjusted analyses also 
7 showed no association between EPA plus DHA levels and early sPTB/PPROM using the 
8 Olsen et al.11,12 quintiles (Table 4).
9 Prior to our analysis samples from 17% (16/96) of our low-risk population sample, 9.0% 
10 (16/178) of our high-risk term birth group and 57% (29/51) of our high-risk early 
11 sPTB/PPROM groups had undergone three freeze thaw cycles (Table S1). The remainder of 
12 samples had undergone no prior freeze:thaw cycles.  We found no statistically significant 
13 difference in DHA, EPA or DHA+EPA levels when comparing samples with and without 
14 prior  freeze thaw cycles, but within the high-risk reference group there was a trend for 
15 slightly lower omega-3 fatty-acid levels in samples that had undergone prior freeze-thaw 
16 cycles. When the logistic regression described in Table 3 was repeated in samples both 
17 without prior freeze:thaw cycles (Table S2) and with prior freeze: thaw cycles (Table S3) 
18 there remained a non-significant trend towards a reduced chance of sPTB/PPROM with 
19 lower omega-3 fatty-acid levels in both analyses.
20
21 DISCUSSION 
22 Contrary to the previous findings, we did not demonstrate a relationship between long-chain 
23 omega-3 levels and spontaneous preterm birth. This was despite comparing plasma total 
24 omega-3, DHA and EPA levels to both ‘healthy’ pregnancies in our population, and to levels 
25 in Danish pregnant women that have previously been associated with preterm birth.11,12 In 
26 our population, both women at high and low risk of preterm birth had lower levels of plasma 
27 DHA plus EPA than those described in the Danish population.11,12
28 The plasma long-chain omega-3 levels within our population could have been so low that we 
29 did not have enough ‘replete’ participants to show the benefit in preterm birth reduction with 
30 adequate levels. However, our results show a non-significant trend in the opposite direction 
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1 to previous literature (i.e. a higher risk of preterm birth with a higher level of omega-3, DHA 
2 and EPA), and no biological gradient.
3 Women with a previous preterm birth are often highly motivated to avoid recurrence, and 
4 could have become aware of evidence to support increased omega-3 intake17,18 during their 
5 pregnancy. Omega-3 fatty acids may have a rapid effect on risk of preterm birth.19,20 If a 
6 substantial number of the women in our study actually did increase their omega-3 fatty acid 
7 intake during pregnancy, this may have confused the relationship between omega-3 measured 
8 in early 2nd trimester and subsequent risk of early preterm birth.
9 To our knowledge this is the fourth analysis relating blood DHA and EPA levels in the 
10 second trimester to preterm birth risk. Previous studies include the analysis by Olsen et al.,11 
11 and the secondary analysis of the ORIP trial,5 both demonstrating lower long-chain omega-3 
12 levels in association with preterm birth under 34 weeks, in Danish and Australian populations 
13 respectively. The third study is a secondary analysis of a trial of omega-3 supplements to 
14 prevent recurrent preterm birth under 37 weeks in the US.21 Klebanoff et al. did find that 
15 participants in the lowest quartile of DHA+EPA had a higher rate of preterm birth (83/176, 
16 47.2%) compared to the highest quartile (63/175, 36%), however their results also did not 
17 reach statistical significance.21 
18 A strength of this study is that our preterm group included only recurrent sPTB, or PPROM, 
19 before 34+0 weeks gestation. We aimed to achieve as pure ‘phenotype’ of spontaneous 
20 preterm birth as possible.  Previous studies into the association between omega-3 levels and 
21 preterm birth have included all births under 34 weeks,5 or 37 weeks,21 or only excluded cases 
22 of preeclampsia prior to 34 weeks.11 It is possible that the benefit of omega-3 to prevent 
23 preterm birth is confined to medically indicated preterm birth from conditions such as 
24 preeclampsia and growth restriction.22 However, the most recent Cochrane review shows no 
25 impact of omega-3 supplementation upon these conditions.3 In keeping with this our initial 
26 visualisation of the relationship between long-chain omega-3 status and early preterm birth in 
27 the whole high-risk group, including those with late medically indicated preterm births 
28 (Figure 2), did not show an association between long-chain omega-3 levels and all preterm 
29 births. Alternatively the impact of omega-3 upon preterm birth prevention may be within the 
30 low-risk population, that was not assessed for preterm birth risk in this study.
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1 A limitation of this study is that 56% of sPTB/PPROM samples had undergone prior 
2 freeze:thaw cycles, in comparison to only 9% of the high-risk reference group. However, we 
3 found higher than expected levels of omega-3 fatty-acids in the sPTB/PPROM group, and 
4 freeze:thaw cycles might be expected to lower the expected levels of omega-3 fatty-acids.12 
5 We therefore do not feel that this has materially impacted upon our findings.
6 We acknowledge that plasma levels of omega-3, DHA and EPA were measured on samples 
7 from participants that were not fasted, however, the previous study finding an association 
8 between plasma levels of DHA and EPA and preterm birth used samples taken by GPs at 
9 routine visits and no mention is made of fasting in the description.11,23
10 This was a pragmatic study based on a biomarker study that had finished recruiting at the 
11 time of study inception. As such no formal power calculation has been performed, and we did 
12 not have a pre-defined a priori level at which we are able to accept/reject our null hypothesis 
13 of no association between long-chain omega-3 levels and recurrent spontaneous early preterm 
14 birth. Nevertheless, we feel that knowledge of the low baseline levels of long-chain omega-3 
15 fatty acids within pregnant women in the UK, and also no indication of an association 
16 between long-chain omega-3 fatty acids and recurrent preterm birth in our high-risk group is 
17 important to inform the discussion about omega-3 supplementation for preterm birth 
18 prevention.
19 It is possible that preterm birth prevention therapy averted preterm birth in some high-risk 
20 participants, attenuating an association between omega-3 and early sPTB/PPROM. Analysis 
21 limited to participants without preterm birth prevention treatment showed similar findings 
22 (data not shown). Any intervention involving omega-3 is likely to be applied in combination 
23 with current treatments, and so we felt it was optimal to assess the situation within current 
24 clinical practice.
25 Preterm birth is a multifactorial disease and the contribution of a single factor (such as 
26 omega-3 levels) is likely to only be modest. It is possible that other factors, genetic or 
27 environmental, leading to recurrent preterm births are able to ‘overpower’ any contribution of 
28 long-chain omega-3 status. We suggest that future research should include baseline long-
29 chain omega-3 fatty acids testing on a large scale, and evaluate the influence of these levels 
30 on other risk factors of preterm birth. This would be relevant to both women with, and 
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1 without, identifiable risk factors for preterm birth, and may be achieved by an individual 
2 patient data meta-analysis of already conducted work.
3 CONCLUSION
4 We found low plasma omega-3, DHA and EPA levels in the second trimester in women at 
5 high and low-risk of preterm birth. The previously described association between low DHA 
6 and EPA and preterm birth was not replicated. We suggest that either plasma long-chain 
7 omega-3 fatty acids were so low in this population we didn’t have enough ‘replete’ 
8 participants to show a benefit, or there are alternative mechanisms for recurrent early preterm 
9 birth in this setting. 
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20 Visualisation of the relationship between long-chain omega-3 fatty acid levels and pregnancy 
21 outcome in women with a previous sPTB/PPROM <34+0 weeks.
22 Table 1
23 Demographic details of the study population. 
24 Table 2
25 Normal distribution of plasma long-chain omega-3 fatty acids in the low-risk population 
26 sample.
Page 16 of 32
http://www.aogs-online.com
































































2 Relationship between quintile of long-chain omega-3 (as defined by the low-risk population 
3 group) and pregnancy outcome in the high-risk group.
4 Table 4
5 Relationship between quintile of fatty acids (as defined by Olsen et al11) and pregnancy 
6 outcome.
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8 Plasma long-chain Omega-3 fatty acid levels compared by pregnancy group and number of 
9 freeze:thaw cycles prior to sample analysis.
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11 Relationship between quintile of long-chain omega-3 (as defined by the low-risk population 
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1 Figure and Table legends
2 Figure 1
3 Participant selection. Two obstetric populations were used to recruit women. The first was 
4 women at high-risk of sPTB based on their history of previous sPTB. The second population 
5 was used to represent “normality” and consisted of women with a history of term birth only.  
6 Two stages of analysis were performed. The first was to visualise the relationship between 
7 long-chain omega-3 status and the occurrence of sPTB or PPROM under 34 weeks in the 
8 high-risk cohort. The second analysis used aetiological modelling to assess the contribution 
9 of long-chain omega-3 to recurrent early preterm birth, for this analysis a  clear ‘split’ in the 
10 preterm and term cases was desired, and so births 34+0-36+6 weeks were excluded from this 
11 analysis.  ‘Cases’ consisted of women with recurrent sPTB or PPROM <34+0 weeks.  sPTB= 
12 Spontaneous Preterm Birth, PPROM=Preterm Prelabour Rupture of Membranes 
13 Figure 2:
14 Visualisation of the relationship between long-chain omega-3 fatty acid levels and pregnancy 
15 outcome in women with a previous sPTB/PPROM <34+0 weeks. Total n=283, of whom 51 
16 had recurrent sPTB/PPROM, and the remainder (n=232) delivered ≥ 34+0 weeks without 
17 PPROM. A-D, histograms showing long-chain omega-3 fatty acid levels by pregnancy 
18 outcome. E-H risk of recurrent early sPTB/PPROM <34+0 weeks by baseline fatty acid status 
19 in women with previous early sPTB or PPROM (n=283). The pale grey lines represent the 
20 95% confidence interval for the risk. P values are for the association between long chain 
21 omega-3 status and risk of early preterm birth using fractional polymonial logistic regression. 
22 Graphs show the unadjusted data. Adjusted P values include the covariates of age, BMI, 
23 smoking and Index of Multiple Deprivation (IMD). Percentages are of the total plasma fatty 
24 acids.
25 Table 1
26 Demographic details of the study population. BMI= Body Mass index, kg/m2. IMD= Index of 
27 Multiple Deprivation. P value calculated by ANOVA for age, Kruskal-Wallis for BMI and 
28 Fisher’s exact test for remainder of analysis. There were 3 missing values for BMI in the 
29 high-risk sPTB or PPROM <34 weeks group and 3 missing values in the high-risk birth ≥37 
30 weeks term group. There was 1 missing value for smoking in the high-risk sPTB or PPROM 
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1 group and 3 missing values in the birth ≥37 weeks group. The IMD data section details the 
2 amount of data available, and all other data sections were complete. The high percentage of 
3 missing data for IMD was because postcode wasn’t recorded for the high-risk group at the 
4 start of the research study.
5
6 Table 2
7 Normal distribution of plasma long-chain omega-3 fatty acids in the low-risk population 
8 sample. Women were parous, with all previous births at term and birth ≥ 39+0 weeks in the 
9 index pregnancy. DHA=Docosahexaenoic acid, EPA=Eicosapentaenoic acid. All values are 
10 percentage of the total plasma fatty acids.
11 Table 3
12 Relationship between quintile of long-chain omega-3 (as defined by the low-risk population 
13 sample) and pregnancy outcome in the high-risk group.. *=adjusted for age, BMI, and 
14 smoking (actual data only), **= adjusted for age, BMI, smoking and index of multiple 
15 deprivation (actual data only) ***= adjusted for age, BMI, smoking and index of multiple 
16 deprivation including imputed data for missing data.
17 Table 4
18 Relationship between quintile of fatty acids (as defined by Olsen et al11) and pregnancy 
19 outcome. *=adjusted for age, BMI, and smoking (actual data only), **= adjusted for age, 
20 BMI, smoking and index of multiple deprivation (actual data only) ***= adjusted for age, 
21 BMI, smoking and index of multiple deprivation including imputed data for missing data.
22 Supplementary Table 1: 
23 Plasma long-chain Omega-3 fatty acid levels compared by pregnancy group and number of 
24 freeze:thaw cycles prior to sample analysis.
25 Supplementary Table 2:
26 Relationship between quintile of long-chain omega-3 (as defined by the low-risk population 
27 sample) and pregnancy outcome in the high-risk group using only samples without prior 
28 freeze:thaw cycles. *=adjusted for age, BMI, and smoking (actual data only).  
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1 Supplementary Table 3:
2 Relationship between quintile of long-chain omega-3 (as defined by the low-risk population 
3 sample) and pregnancy outcome in the high-risk group using only samples with prior 
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NA Early term delivery 37+0-38+6 (low risk only) 74
NA sPTB or PPROM  <34+0 weeks in low risk cohort 2
2 Caregiver initiated preterm birth <34+0 weeks 0
0 No outcome data 2
4 Intrauterine death 0
4 No sample available for analysis 0
N=296
Included in visualisation
n=51 with sPTB or PPROM 16+0-33+6 weeks
n=232 without sPTB or PPROM 16+0-33+6 weeks
High-risk early Preterm
n=51




(Parous women with all previous births at term)
High-risk pregnancy
(Previous sPTB or PPROM 16+0-33+6 weeks)
High-risk term birth
n=178




Birth ≥ 39+0 weeks
1) Visualisation of relationship 
between long chain omega 3 status 
and risk of preterm birth in high-risk 
pregnancies
2) Assessment of the contribution 
of long chain omega-3 status to 
recurrent early preterm birth with 
reference to the distribution in the 
low-risk group
N High risk excluded from aetiological model
28 sPTB or PPROM 34+0 - 36+6 weeks








3 Omega 3 supplements used 4
N=283
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Long-chain omega 3 fatty acid levels by 
pregnancy outcome 
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n SD/IQR/% n SD/IQR/% n SD/IQR/% n SD/IQR/%
283 178 51 96
30.4 5.1 30.6 5.1 30.8 5 31.2 4.2 0.829 0.375
24.6 21.8-28.7 25.0 21.8-28.9 25.6 23.1-32.5 23.6 21.9-27.6 0.208 0.209
68 24.0 37 20.9 13.0 26.5 9 9.7 0.438 0.011
1 (most deprived) 127 67.2 82 67.2 21 75.0 47 49.4
2 18 9.5 9 7.3 3 10.7 15 15.8
3 19 10.1 11 9.0 2 7.1 19 20.0
4 17 9.0 13 10.7 2 7.1 11 11.6
5 (least deprived) 8 4.2 7 5.7 0 0 3 3.2
Number of participants included in IMD data 189 66.8 122 68.5 28 54.9 95 99.0
0 0 0 0 0 0 0 96 100
1 242 85.5 163 91.6 37 72.5
≥ 2 41 14.5 15 8.4 14 27.4
None 254 89.8 167 93.8 42 82.4 88 91.7
≤1x LLETZ <10mm 19 6.7 9 5.1 6 11.8 8 8.3
1x LLETZ ≥10mm/≥2 LLETZ/knife cone biopsy 10 3.5 2 1.1 3 5.9
No 190 67.1 128 71.9 27 52.9 96 100
Yes 93 32.9 50 28.1 24 47.1
37+5 35+3-39+1 38+6 38+0-39+6 31+2 26+1-33+2 40+2 39+3-41+0
2800 809 3238 477 1576 703 3614 439
Preterm prelabour rupture of membranes <34 weeks (n, %) 21 7.42 0 0 21 46 0 0
Gestational age at birth in weeks + days (median, IQR)













Birth ≥37 weeks (term)
sPTB/ PPROM <34 weeks
(preterm)













Birth ≥ 39 weeks
Define expected
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20th 40th 60th 80th
Total saturates 36.9 (2.36) 29.9-42.8 35.2 36.2 36.9 38.8
Total monosaturates 29.3 (2.91) 21.4-37.5 27.0 28.8 30.2 31.6
Omega 6 30.8 (3.50) 21.4-39.7 27.4 30.2 31.8 33.6
Omega 3 2.65 (0.49) 1.87-4.09 2.18 2.51 2.74 3.07
EPA 0.32 (0.12) 0.14-0.77 0.22 0.27 0.31 0.37
DHA 1.35 (0.32) 0.73-2.14 1.10 1.22 1.38 1.62
EPA +DHA 1.67 (0.39) 0.95-2.88 1.36 1.51 1.70 1.98
Arachidonic acid 4.83 (0.9) 2.79-7.03 4.16 4.51 5.07 5.51
Component of fatty acids
Percentiles
Percentage of total fatty acids in low risk population sample (previous term births),
birth ≥39 weeks in index pregnancy n=96
Mean (SD) Range
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1 1.69-2.18 27 5 9.8 22 12.4 0.65 0.23-1.84 0.42 0.63 0.21-1.85 0.40 0.83 0.23-2.98 0.77 0.51 0.14-1.78 0.29
2 2.18-2.51 59 9 17.6 50 28.1 0.52 0.23-1.15 0.11 0.58 0.25-1.33 0.20 0.86 0.30-2.52 0.79 0.48 0.18-1.24 0.13
3-5 2.51-5.29 143 37 72.5 106 59.6 1 1 - 1 1 - 1 1 - 1 1 -
1 0.88-1.36 37 8 15.7 29 16.3 0.91 0.38-2.15 0.83 1.04 0.43-2.54 0.93 0.88 0.26-2.98 0.84 0.75 0.27-2.10 0.58
2 1.36-1.51 29 5 9.8 24 13.5 0.69 0.24-1.91 0.47 0.69 0.24-2.01 0.50 1.64 0.49-5.55 0.42 0.60 0.18-2.03 0.41
3-5 1.51-4.1 163 38 74.5 125 70.2 1 1 - 1 1 -
1 0.72-1.1 32 7 13.7 25 14.0 0.93 0.37-2.30 0.87 1.07 0.42-2.73 0.89 0.71 0.18-2.75 0.62 0.73 0.24-2.18 0.57
2 1.10-1.22 29 5 9.8 24 13.5 0.69 0.24-1.93 0.48 0.76 0.27-2.16 0.60 1.31 0.41-4.17 0.64 0.82 0.26-2.63 0.74
3-5 1.22-3.10 168 39 76.5 129 72.5 1 1 - 1 1 - 1 1 - 1 1 -
1 0.07-0.22 53 8 15.7 45 25.3 0.53 0.22-1.24 0.14 0.55 0.23-1.32 0.18 0.45 0.13-1.57 0.21 0.35 0.12-1.03 0.06
2 0.22-0.27 53 12 23.5 41 23.0 0.87 0.41-1.86 0.72 0.83 0.37-1.85 0.64 0.61 0.21-1.77 0.36 0.57 0.22-1.48 0.25
3-5 0.27-1.18 123 31 60.8 92 51.7 1 1 - 1 1 - 1 1 - 1 1 -





Crude OR of PTB compared to quintile 3-5
within high risk (n=229)
%








































P - value95%CI 95%CI
Level (%)
Adjusted* OR compared to quintile 3-
5 within high risk (n=220)
Quintile
Adjusted*** OR compared to quintile




95%CI P - value
Adjusted** OR compared to quintile 3-
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1 0.47-1.42 25 26.0 8 15.7 40 22.5 0.62 0.26-1.51 0.30 0.72 0.29-1.78 0.48 0.58 0.17-2.04 0.40 0.61 0.25-1.51 0.29
2 1.43-1.74 38 39.6 18 35.3 60 33.7 0.94 0.47-1.87 0.852 0.97 0.47-2.03 0.94 1.52 0.57-4.04 0.40 0.87 0.42-1.79 0.71
3-5 1.74-4.95 33 34.4 25 49.0 78 43.8 1 1 - 1 1 - 1 1 - 1 1 -
Total 96 100 51 100 178 100
Crude OR of PTB compared to quintile 3-5
within high risk (n=229)
Adjusted* OR compared to quintile 3-5
within high risk (n=220)
95%CI P - value
n % n % n %
Quintile Value
Birth ≥39 weeks
Adjusted** OR compared to quintile 3-5
within high risk (n=146)
Adjusted*** OR compared to quintile 3-





















Birth ≥37 weeks OR of early
sPTB/PPROM
(95% CI)
95%CI P - value
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median IQR median IQR median IQR median IQR median IQR median IQR
DHA 1.34 0.43 1.27 0.32 0.81 1.39 0.42 1.40 0.57 0.96 1.42 0.48 1.40 0.50 0.63
EPA 0.29 0.13 0.30 0.09 0.51 0.28 0.15 0.26 0.16 0.52 0.33 0.16 0.27 0.19 0.17
DHA+EPA 1.61 0.53 1.64 0.41 0.98 1.69 0.49 1.63 0.61 0.73 1.83 0.61 1.70 0.53 0.57
3 freeze thaw cycles n=29 Mann-
Whitney P
Low-risk term High-risk term High-risk early sPTB/PPROM
0 freeze thaw cycles n=80 3 freeze thaw cycles n=16 Mann-
Whitney p
0 freeze thaw cycles n=162 3 freeze thaw cycles n=16 Mann-
Whitney P
0 freeze thaw cycles n=22
Table S1: Plasma long-chain Omega 3 fatty acid levels compared by pregnancy group and number of freeze:thaw cycles prior to sample 
analysis.
Page 30 of 32
http://www.aogs-online.com






























































1 1.69-2.18 22 2 9.1 20 12.3 0.66 0.14-3.11 0.60 0.74 0.15-3.67 0.71
2 2.18-2.51 48 5 22.7 43 26.5 0.77 0.26-2.24 0.63 0.98 0.32-3.02 0.98
3-5 2.51-5.29 114 15 68.2 99 61.1 1 1 - 1 1 -
1 0.88-1.36 28 2 9.1 26 16.0 0.52 0.11-2.39 0.40 0.60 0.13-2.84 0.52
2 1.36-1.51 24 3 13.6 21 13.0 0.97 0.26-3.59 0.96 1.11 0.29-4.31 0.88
3-5 1.51-4.1 132 17 77.3 115 71.0 1 1 - 1 1 -
1 0.72-1.1 24 2 9.1 22 13.6 0.63 0.14-2.93 0.56 0.74 0.15-3.57 0.71
2 1.10-1.22 25 3 13.6 22 13.6 0.95 0.26-3.50 0.93 1.07 0.28-4.07 0.92
3-5 1.22-3.10 135 17 77.3 118 72.8 1 1 - 1 1 -
1 0.07-0.22 42 2 9.1 40 24.7 0.25 0.06-1.13 0.07 0.29 0.06-1.35 0.11
2 0.22-0.27 40 3 13.6 37 22.8 0.41 0.11-1.47 0.17 0.46 0.12-1.72 0.25
3-5 0.27-1.18 102 17 77.3 85 52.5 1 1 - 1 1 -
1 0.47-1.42 39 2 9.1 37 1.2 0.32 0.07-1.53 0.15 0.38 0.08-1.84 0.23
2 1.43-1.74 61 8 36.4 53 4.9 0.91 0.35-2.37 0.84 0.95 0.33-2.74 0.93
3-5 1.74-4.95 84 12 54.5 72 7.4 1 1 - 1 1 -














High-risk (previous sPTB or PPROM 16-33+6 weeks)




Crude OR of PTB compared to quintile 3-5 within high risk
(n=45)
Adjusted* OR compared to quintile 3-5 within high
risk (n=44)
Recurrent early sPTB or
PPROM <34 weeks
Birth ≥37 weeks OR of early
sPTB/PPROM (95% CI)
n=184








Table S2: Relationship between quintile of long-chain omega 3 (as defined by the low-risk reference group) and pregnancy outcome in the high-
risk group using only samples without prior freeze:thaw cycles. *=adjusted for age, BMI, and smoking (actual data only).
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Table S3: Relationship between quintile of long-chain omega 3 (as defined by the low-risk reference group) and pregnancy outcome in the high-
risk group using only samples with prior freeze:thaw cycles. *=adjusted for age, BMI, and smoking (actual data only). 
1 1.69-2.18 5 3 10.3 2 12.5 0.48 0.07-3.46 0.46 0.43 0.05-3.50 0.43
2 2.18-2.51 11 4 13.8 7 43.8 0.18 0.04-0.81 0.03 0.18 0.03-0.96 0.05
3-5 2.51-5.29 29 22 75.9 7 43.8 1 1 - 1 1 -
1 0.88-1.36 9 6 20.7 3 18.8 0.95 0.20-4.61 0.95 1.67 0.32-8.68 0.55
2 1.36-1.51 5 2 6.9 3 18.8 0.32 0.046-2.21 0.25 0.44 0.04-4.57 0.50
3-5 1.51-4.1 31 21 72.4 10 62.5 1 1 - 1 1 -
1 0.72-1.1 8 5 17.2 3 18.8 0.83 0.16-4.14 0.82 1.29 0.24-7.05 0.77
2 1.10-1.22 4 2 6.9 2 12.5 0.50 0.06-4.03 0.52 0.69 0.07-7.00 0.75
3-5 1.22-3.10 33 22 75.9 11 68.8 1 1 - 1 1 -
1 0.07-0.22 11 6 20.7 5 31.3 0.60 0.13-2.67 0.50 0.72 0.14-3.59 0.69
2 0.22-0.27 13 9 31.0 4 25.0 1.13 0.25-4.98 0.88 0.99 0.19-5.10 0.99
3-5 0.27-1.18 21 14 48.3 7 43.8 1 1 - 1 1 -
1 0.47-1.42 9 6 10.3 3 18.8 0.92 0.17-5.00 0.93 1.43 0.25-8.27 0.69
2 1.43-1.74 17 10 24.1 7 43.8 0.66 0.17-2.59 0.55 0.53 0.11-2.46 0.42
3-5 1.74-4.95 19 13 20.7 6 37.5 1 1 - 1 1 -






















Adjusted* OR compared to quintile 3-5
within high risk (n=44)
Recurrent early
sPTB/PPROM
Birth ≥37 weeks OR of early
sPTB/PPROM
(95% CI)





High-risk (previous sPTB or PPROM 16-33+6 weeks)
Crude OR of PTB compared to quintile 3-5
within high risk (n=45)
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